ATE232393T1 - Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung - Google Patents

Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung

Info

Publication number: ATE232393T1
Authority: AT; Austria
Prior art keywords: substances; wound healing; production; medicinal products; oxytocin
Prior art date: 1997-03-27

Application number

AT98912862T

Other languages

English (en)

Inventor

Thomas Lundeberg

Moberg Kerstin Uvnaes

Original Assignee

Entretech Medical Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-27

Filing date

1998-03-26

Publication date

2003-02-15

1998-03-26 Application filed by Entretech Medical Ab filed Critical Entretech Medical Ab

2003-02-15 Application granted granted Critical

2003-02-15 Publication of ATE232393T1 publication Critical patent/ATE232393T1/de

Links

XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title abstract 3
101800000989 Oxytocin Proteins 0.000 title abstract 3
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title abstract 3
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title abstract 3
229960001723 oxytocin Drugs 0.000 title abstract 3
239000000126 substance Substances 0.000 title abstract 2
230000029663 wound healing Effects 0.000 title abstract 2
229940126601 medicinal product Drugs 0.000 title 1
206010052428 Wound Diseases 0.000 abstract 2
208000027418 Wounds and injury Diseases 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
230000001684 chronic effect Effects 0.000 abstract 1
238000009109 curative therapy Methods 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

AT98912862T 1997-03-27 1998-03-26 Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung ATE232393T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9701162A SE9701162D0 (sv)	1997-03-27	1997-03-27	New use II
PCT/SE1998/000554 WO1998043661A1 (en)	1997-03-27	1998-03-26	Use of substances having oxytocin activity for preparation of medicaments for wound healing

Publications (1)

Publication Number	Publication Date
ATE232393T1 true ATE232393T1 (de)	2003-02-15

Family

ID=20406369

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98912862T ATE232393T1 (de)	1997-03-27	1998-03-26	Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung

Country Status (10)

Country	Link
US (1)	US6262021B1 (de)
EP (1)	EP1003542B1 (de)
JP (1)	JP2001519786A (de)
CN (1)	CN1251530A (de)
AT (1)	ATE232393T1 (de)
AU (1)	AU749479B2 (de)
DE (1)	DE69811371T2 (de)
ES (1)	ES2194308T3 (de)
SE (1)	SE9701162D0 (de)
WO (1)	WO1998043661A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080004224A1 (en) *	1994-05-04	2008-01-03	Hlavka Joseph J	Dermatological uses of tri-, tetra-, penta-, and polypeptides
SE9701184D0 (sv) *	1997-04-01	1997-04-01	Karolinska Innovations Ab	Substanser för att åstadkomma preferens och skapa acceptans
SE9803272D0 (sv) *	1998-09-25	1998-09-25	Kerstin Uvnaes Moberg	A drug for cell regeneration
SE0001440D0 (sv) *	2000-04-18	2000-04-18	Entretech Medical Ab	A drug against climacteric disorders
SE0100684D0 (sv) *	2001-02-28	2001-02-28	Kerstin Uvnaes Moberg	New subject-matter
KR100441167B1 (ko) *	2001-12-27	2004-07-21	씨제이 주식회사	마이크로에멀젼 예비 농축액 조성물
EP1468690B1 (de) *	2003-03-27	2008-10-08	Pantarhei Bioscience B.V.	Verwendung von Estrogenen zur Behandlung von Männerunfruchtbarkeit
JO2937B1 (en)	2004-08-11	2016-03-15	فيرينغ.بي.في	Tight muscles of the peptide vascular tensioner receptor
JP4747364B2 (ja) *	2005-04-04	2011-08-17	独立行政法人産業技術総合研究所	紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
US7660413B2 (en) *	2005-04-08	2010-02-09	Shahram Partovi	Secure digital couriering system and method
WO2007025286A2 (en) *	2005-08-26	2007-03-01	The Board Of Trustees Of The Leland Stanford Junior University	Therapy procedure for drug delivery for trigeminal pain
NZ569836A (en) *	2006-02-10	2010-09-30	Ferring Bv	Novel compounds
US20080004223A1 (en) *	2006-05-17	2008-01-03	Hlavka Joseph J	Dermatological uses of the tripeptide melanocyte stimulating inhibitory factor (mif)
US9050286B2 (en) *	2007-08-14	2015-06-09	Ferring B.V.	Use of peptidic vasopression receptor agonists
KR20100061680A (ko) *	2007-09-11	2010-06-08	몬도바이오테크 래보래토리즈 아게	치료제로서의 ｇｌｙ－ｐｒｏ－ｇｌｕ－ｏｈ（ｇｐｅ）의 용도
WO2009040020A1 (en) *	2007-09-11	2009-04-02	Mondobiotech Laboratories Ag	Amylin as a therapeutic agent
AU2008303955A1 (en) *	2007-09-11	2009-04-02	Mondobiotech Laboratories Ag	Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of Pseudomonas aeruginosa infection
WO2009033820A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
WO2009039983A2 (en) *	2007-09-11	2009-04-02	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
US8071555B2 (en) *	2007-10-29	2011-12-06	Helix Biomedix Inc.	Protective skin care peptides
AU2011252764B2 (en) *	2010-05-14	2012-12-13	Charlotte L. Keating	Neuropsychopharmacological treatment regimes for treating psychological disorders
ES2667532T3 (es) *	2010-06-18	2018-05-11	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Neogénesis del folículo piloso
US9585935B2 (en) *	2010-07-30	2017-03-07	The Regents Of The University Of California	Intranasal oxytocin treatment to improve schizophrenia
SE536091C2 (sv)	2011-04-14	2013-04-30	Pep Tonic Medical Ab	Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
US20130040923A1 (en)	2011-05-13	2013-02-14	Trimel Pharmaceuticals Corporation	Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
DE102011118016A1 (de) *	2011-10-26	2013-05-02	Henkel Ag & Co. Kgaa	Kosmetische Mittel enthaltend Oxytocin und Riechstoffe
US9387183B2 (en)	2011-12-28	2016-07-12	Kuwait University	Method of treating diabetes-related impaired wound healing
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
JP6469655B2 (ja)	2013-05-03	2019-02-13	ザヘンリーエム．ジャクソンファウンデーションフォーザアドヴァンスメントオブミリタリーメディシンインコーポレイテッド	代用皮膚および毛包新生の方法
AU2015270723A1 (en)	2014-06-03	2016-11-17	F. Hoffmann-La Roche Ag	Peptides as oxytocin agonists
US11389473B2 (en)	2015-01-07	2022-07-19	Tonix Pharmaceuticals Holding Corp.	Magnesium-containing oxytocin formulations and methods of use
MX2018012351A (es)	2016-04-12	2019-02-07	Trigemina Inc	Formulaciones de oxitocina que contienen magnesio y metodos de uso.
CN107456570A (zh) *	2017-07-31	2017-12-12	温州医科大学附属第二医院、温州医科大学附属育英儿童医院	催产素在促进缺血超长随意皮瓣存活中的作用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3274060A (en) *	1962-05-23	1966-09-20	Armour Pharma	Treatment of multiple sclerosis with oxytocin
NL129421C (de) *	1963-08-30	1900-01-01
WO1988005661A1 (en)	1987-01-30	1988-08-11	Biomed Research Consultants, Limited	Vasopressin-based pharmaceutical compositions
US5175144A (en) *	1988-11-29	1992-12-29	The Johns Hopkins University	Method of retarding the progression of chronic renal failure
SE9701161D0 (sv) *	1997-03-27	1997-03-27	Karolinska Innovations Ab	New use I

1997
- 1997-03-27 SE SE9701162A patent/SE9701162D0/xx unknown
1998
- 1998-03-26 ES ES98912862T patent/ES2194308T3/es not_active Expired - Lifetime
- 1998-03-26 AU AU67550/98A patent/AU749479B2/en not_active Ceased
- 1998-03-26 US US09/381,799 patent/US6262021B1/en not_active Expired - Lifetime
- 1998-03-26 DE DE69811371T patent/DE69811371T2/de not_active Expired - Lifetime
- 1998-03-26 AT AT98912862T patent/ATE232393T1/de active
- 1998-03-26 CN CN98803766A patent/CN1251530A/zh active Pending
- 1998-03-26 JP JP54154798A patent/JP2001519786A/ja not_active Ceased
- 1998-03-26 WO PCT/SE1998/000554 patent/WO1998043661A1/en not_active Ceased
- 1998-03-26 EP EP98912862A patent/EP1003542B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69811371D1 (de)	2003-03-20
JP2001519786A (ja)	2001-10-23
EP1003542A1 (de)	2000-05-31
SE9701162D0 (sv)	1997-03-27
DE69811371T2 (de)	2003-12-18
AU749479B2 (en)	2002-06-27
WO1998043661A1 (en)	1998-10-08
EP1003542B1 (de)	2003-02-12
AU6755098A (en)	1998-10-22
CN1251530A (zh)	2000-04-26
ES2194308T3 (es)	2003-11-16
US6262021B1 (en)	2001-07-17

Legal Events

Date

Code

Title

Description

2003-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1003542

Country of ref document: EP

Publication	Publication Date	Title
DE69811371D1 (de)	2003-03-20	Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung
DE59911740D1 (de)	2005-04-14	Topisch anwendbare mittel gegen nagelpilzerkrankungen
ATE274916T1 (de)	2004-09-15	Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
SE9401406D0 (sv)	1994-04-25	Pharmaceutical products for curing tumourous diseases and process for preparing same
ATE415962T1 (de)	2008-12-15	Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
NO20022998D0 (no)	2002-06-21	Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
DE69937562D1 (de)	2007-12-27	Verbessertes angereichertes blutplättchen wundheilmittel
DE69902234D1 (de)	2002-08-29	Matrixprotein enthaltende zusammensetzungen zur wundheilung
DE69531098D1 (de)	2003-07-24	Piperidine und pyrrolidine
ES2181165T3 (es)	2003-02-16	Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
HUP9602498A2 (hu)	1998-04-28	Antimikrobiális hatású gyógyászati készítmények
ATE269077T1 (de)	2004-07-15	Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE68910973D1 (de)	1994-01-05	Arzneimittelzusammensetzung, enthaltend deoxyribonukleoside für heilung von wunden.
ATE55695T1 (de)	1990-09-15	Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATE275966T1 (de)	2004-10-15	Activin stimulator enthaltende pharmazeutische zusammensetzung
DE69910202D1 (de)	2003-09-11	EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
ATE281159T1 (de)	2004-11-15	Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
ES2191449T3 (es)	2003-09-01	Derivados de ciclopentabenzofurano y su uso.
ATE252383T1 (de)	2003-11-15	Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
MX9202366A (es)	1992-11-01	Nuevas 2-amino-5-ciano-1,4-di hidro piridinas y procedimiento para su fabricacion.
DE59704194D1 (de)	2001-09-06	Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
DE68905657D1 (de)	1993-05-06	Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE69531554D1 (de)	2003-09-25	Verwendung von inosittriphosphat zur herstellung von arzneimitteln
ATE234613T1 (de)	2003-04-15	Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE59805246D1 (de)	2002-09-26	Tissue-faktor zur beeinflussung von gefässbildung